Aquestive Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $44.5M | $57.6M | $50.6M | $47.7M | $50.8M |
| Operating income | -$71.1M | -$30.8M | -$15.1M | -$42.1M | -$34.7M |
| Operating expenses | — | — | — | $89.7M | $85.5M |
| Cost of revenue | $18.6M | $17.9M | $20.8M | $19.4M | — |
| Cash from operations | -$52.4M | -$35.8M | -$6.4M | -$9.8M | -$33.0M |
| Capital expenditure | $562,000 | $159,000 | $995,000 | $1.0M | $913,000 |
| Free cash flow | -$53.0M | -$35.9M | -$7.4M | -$10.8M | -$33.9M |
| Impairments | $0 | $0 | $216,000 | $0 | — |
| Total assets | $160.4M | $101.4M | $57.4M | $57.1M | $62.0M |
| Total liabilities | $194.1M | $161.6M | $163.9M | $175.6M | $144.1M |
Shares outstanding 125.5M · Free float 91.7%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.